6-三氟甲氧基-3-吲唑甲酸 | 869782-97-8

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 6-三氟甲氧基-3-吲唑甲酸
• 中文别名: 6-三氟甲氧基-1H-吲唑-3-羧酸
• 英文名称: 6-(trifluoromethoxy)-1H-indazole-3-carboxylic acid
• CAS: 869782-97-8
• 化学式: C₉H₅F₃N₂O₃
• mdl: MFCD06739136
• 分子量: 246.146
• InChiKey: DBSBRTKNVSHDMD-UHFFFAOYSA-N

物化性质

• 沸点：
  401.9±40.0 °C(Predicted)
• 密度：
  1.662±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  75.2
• 氢给体数：
  2
• 氢受体数：
  7

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Trifluoromethoxy-3-indazolecarboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Trifluoromethoxy-3-indazolecarboxylic acid
CAS number: 869782-97-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H5F3N2O3
Molecular weight: 246.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-三氟甲氧基-3-吲唑甲酸 、 (S)-(+)-3-喹宁醇 在 吡啶 、 对甲苯磺酰氯 作用下， 反应 16.0h， 以16%的产率得到(3S)-1-azabicyclo[2.2.2]oct-3-yl 6-(trifluoromethoxy)-1H-indazole-3-carboxylate
  参考文献：
  名称：

  WO2006/69097

  摘要：

  公开号：

文献信息

• [EN] SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK<br/>[FR] SALICYLAMIDES DE SPIROHEPTANE ET COMPOSÉS ASSOCIÉS UTILISÉS COMME INHIBITEURS DE ROCK
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017123860A1

  公开（公告）日：2017-07-20

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了式(I)的化合物：或立体异构体、互变异构体或药用可接受的盐，其中所有变量如本文所述定义。这些化合物是选择性的ROCK抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用同一化合物治疗心血管、平滑肌、肿瘤学、神经病理学、自身免疫、纤维化和/或炎症性疾病的方法。
• [EN] AMIDE DERIVATIVES AS TTX-S BLOCKERS<br/>[FR] DÉRIVÉS D'AMIDE COMME BLOQUEURS DE TTX-S
  申请人：RAQUALIA PHARMA INC

  公开号：WO2013161308A1

  公开（公告）日：2013-10-31

  The present invention relates to amide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及酰胺衍生物，具有对电压门控钠通道（如TTX-S通道）的阻塞活性，可用于治疗或预防涉及电压门控钠通道的疾病和疾病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及电压门控钠通道的疾病中使用这些化合物和组合物。
• [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR TRAITER DES ÉTATS PATHOLOGIQUES ASSOCIÉS À UNE ACTIVITÉ DE STING
  申请人：IFM DUE INC

  公开号：WO2022015938A1

  公开（公告）日：2022-01-20

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

  本公开涉及化学实体（例如，一种化合物或药用可接受盐，和/或水合物，和/或共晶体，和/或该化合物的药物组合），其抑制（例如，对抗）干扰素基因激活剂（STING）。所述化学实体可用于治疗病症、疾病或障碍，其中增加（例如，过度）STING激活（例如，STING信号传导）导致该病症、疾病或障碍的病理和/或症状和/或进展（例如，癌症）在受试者（例如，人类）中。本公开还涉及含有相同化学实体的组合物，以及使用和制备相同的方法。
• Nicotinic alpha-7 receptor ligands and preparation and uses thereof
  申请人：Nguyen Minh Truc

  公开号：US20060167039A1

  公开（公告）日：2006-07-27

  The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

  本发明通常涉及烟碱乙酰胆碱受体(nAChR)配体领域，nAChRs的激活以及与缺陷或功能失调的烟碱乙酰胆碱受体相关的疾病情况的治疗，特别是大脑。此外，本发明涉及作为α7 nAChR亚型配体的新化合物，制备这种化合物的方法，含有这种化合物的组合物以及其使用方法。
• NICOTINIC ALPHA-7 RECEPTOR LIGANDS AND PREPARATION AND USES THEREOF
  申请人：Nguyen Truc Minh

  公开号：US20100016351A1

  公开（公告）日：2010-01-21

  The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

  本发明通常涉及神经元乙酰胆碱受体（nAChR）的配体、nAChR的激活以及与缺陷或故障的神经元乙酰胆碱受体相关的疾病状态的治疗，特别是大脑的治疗。此外，本发明涉及一种新的化合物，其作为α7 nAChR亚型的配体，制备这种化合物的方法，含有这种化合物的组合物以及使用这种化合物的方法。